RxDoctor Payments Data

Kristen Derosa

Acute Care · Worcester, MANPI 1003469230

Payments from drug & device makers

$329in general payments, 2019–2025

Across 14 payments — averaging $23.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$98
  • Cequr Corporation$75
  • Sunovion Pharmaceuticals Inc.$37
  • Johnson & Johnson$19
  • Otsuka America Pharmaceutical, Inc.$17
  • GSK$17
  • plus $65 from 5 others

What the payments were for

  • Food & beverage$31796%
  • Education$124%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$329 in reported general payments places this provider in the 60th percentile of 307 acute care providers in Massachusetts.

See all acute care providers in Massachusetts

Medicare billing

Part B allowed, 2024
$130,581
Medicare patients
279
Services billed
1,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide30$36,091
MounjaroTirzepatide31$31,534
FarxigaDapagliflozin Propanediol28$28,051
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog49$25,197
Fiasp FlextouchInsulin Aspart (Niacinamide)26$25,031
JardianceEmpagliflozin17$18,549
Soliqua 100-33Insulin Glargine/Lixisenatide16$16,620
RybelsusSemaglutide16$15,634
Tresiba Flextouch U-200Insulin Degludec13$14,044
Lantus SolostarInsulin Glargine,hum.Rec.Anlog61$9,022
JanuviaSitagliptin Phosphate14$7,844
Humalog Kwikpen U-100Insulin Lispro13$5,951
Nano 2nd Gen Pen NeedlePen Needle, Diabetic48$4,375
Fentanyl11$3,046
Ultra-Fine Short Pen NeedlePen Needle, Diabetic12$1,764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$12$67,62661 claims
AstraZenecaFarxiga$17$28,05128 claims
Boehringer IngelheimJardiance$16$18,54917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 307 acute care providers in Massachusetts.

Other acute care in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →